欧非亚裔有不同的药物吸收基因
路透社新奥尔兰健康消息 美国密苏里州华盛顿大学医学院的霍华德·L·麦克利欧德博士近日在美国新奥尔兰举行的美国癌症研究协会年会上作出报告：与非裔人相比，一种可以增加人体对治疗艾滋病药物及癌症化疗药物的吸收的基因变异在欧洲人和亚洲人身上更常见。研究人员相信，终有一天，这个发现会帮助医生为病人选取最有效的治疗方法。
P-醣蛋白(PGP)已被发现是一种对许多药都有抗药性的蛋白。可以驱使某些抗癌药物离开癌症细胞，从而导致药物失效。当生产PGP的基因发生变异时，即可削弱上述PGP可令药物离开癌症细胞的作用。
麦克利欧德及其分别来自阿伯丁大学、加纳大学医学院及位于沙特阿拉伯的利雅得军事医院的同事们对来自十个种族的1280人的基因结构进行了分析，并把他们分为三类：拥有两种变异基因的人(分别来自父、母亲)；拥有两种正常基因；还有一种人可以拥有一种正常基因和一种变异基因。
, http://www.100md.com 结果发现，在来自加纳、肯尼亚、苏丹，以及非洲裔美国人当中，含有正常基因的比例介于73%-84%之间。相比之下，在英国白人、葡萄牙人、西南亚洲人、中国人、菲律宾人及沙特阿拉伯人当中，该比例仅为34%-59%。拥有两种变异基因的人比拥有两种正常基因的人含有的PGP少四倍。换句话说，就是非洲裔人士比欧亚裔人士含有的PGP为多。而PGP影响抗癌药物以及某些治疗艾滋病药物的效力。
研究者指出，研究的第二步将是看看仅有少量PGP的具有变异基因的人是否比具有正常基因的人对化学疗法有更好的反应。
Drug Absorption Gene Differs in Some Ethnicities
NEW ORLEANS (Reuters Health) - A gene mutation that influences how the body absorbs HIV (news - web sites) medications and chemotherapy drugs is more common in Europeans and Asians than among those of African heritage, an international group of researchers has found.
, 百拇医药
This finding may one day help doctors decide which therapies work best for some patients, Dr. Howard L. McLeod of Washington University School of Medicine in St. Louis, Missouri, reported Sunday at the American Association for Cancer Research‘s annual meeting held in New Orleans, Louisiana.
P-glycoprotein (PGP), also known as the multidrug-resistance protein, pumps certain cancer drugs out of cancer cells, rendering them ineffective. The researchers looked at a variation in the gene that produces PGP. This mutation reduces PGP function, making it less able to force drugs out of cells.
, 百拇医药
McLeod and colleagues from the University of Aberdeen, the University of Ghana Medical School and the Riyadh Armed Forces Hospital in Saudi Arabia, analyzed the genetic makeup of 1,280 people from 10 ethnic groups.
People who have two versions of the mutated gene--one inherited from each parent--have more than four times less PGP than those with two normal versions of the gene. People may also have one normal gene and one mutated one.
, 百拇医药
Among individuals from Ghana, Kenya, the Sudan, as well as African Americans, frequency of the normal gene ranged from 73% to 84%. In contrast, the frequency was 34% to 59% among British whites, Portuguese, Southwest Asian, Chinese, Filipino and Saudi populations.
Because PGP affects the effectiveness of cancer drugs and also certain HIV medications, the high frequency of the normal gene among individuals of African origin may have relevance to how these individuals are cared for, McLeod told the audience at a press briefing.
, http://www.100md.com
The next step in his research, McLeod said in a statement, will be to see if people with the mutated version of the gene--who likely have less PGP--respond better to chemotherapy than those with a non-mutated, normal version.
``People ask, when will genomic information be of use to individual patients? This presentation shows that today is that day,‘‘ Dr. Jeffrey Trent, of the National Human Genome Research Institute in Bethesda, Maryland, said in summary comments. ``Now we can tailor treatment, dosage, drug combinations.‘‘
, http://www.100md.com
Trent told Reuters Health, ``There‘s no doubt we‘re moving to an area where data rules. The ability to access tools that allow us to link information is going to be the critical common denominator internationally.‘‘
He added, ``The problem is linking the data, merging information between centers while being sensitive to current laws and guidelines that prohibit us from moving data without consent. These are the areas that are going to be particularly challenging to us.‘‘, 百拇医药
P-醣蛋白(PGP)已被发现是一种对许多药都有抗药性的蛋白。可以驱使某些抗癌药物离开癌症细胞，从而导致药物失效。当生产PGP的基因发生变异时，即可削弱上述PGP可令药物离开癌症细胞的作用。
麦克利欧德及其分别来自阿伯丁大学、加纳大学医学院及位于沙特阿拉伯的利雅得军事医院的同事们对来自十个种族的1280人的基因结构进行了分析，并把他们分为三类：拥有两种变异基因的人(分别来自父、母亲)；拥有两种正常基因；还有一种人可以拥有一种正常基因和一种变异基因。
, http://www.100md.com 结果发现，在来自加纳、肯尼亚、苏丹，以及非洲裔美国人当中，含有正常基因的比例介于73%-84%之间。相比之下，在英国白人、葡萄牙人、西南亚洲人、中国人、菲律宾人及沙特阿拉伯人当中，该比例仅为34%-59%。拥有两种变异基因的人比拥有两种正常基因的人含有的PGP少四倍。换句话说，就是非洲裔人士比欧亚裔人士含有的PGP为多。而PGP影响抗癌药物以及某些治疗艾滋病药物的效力。
研究者指出，研究的第二步将是看看仅有少量PGP的具有变异基因的人是否比具有正常基因的人对化学疗法有更好的反应。
Drug Absorption Gene Differs in Some Ethnicities
NEW ORLEANS (Reuters Health) - A gene mutation that influences how the body absorbs HIV (news - web sites) medications and chemotherapy drugs is more common in Europeans and Asians than among those of African heritage, an international group of researchers has found.
, 百拇医药
This finding may one day help doctors decide which therapies work best for some patients, Dr. Howard L. McLeod of Washington University School of Medicine in St. Louis, Missouri, reported Sunday at the American Association for Cancer Research‘s annual meeting held in New Orleans, Louisiana.
P-glycoprotein (PGP), also known as the multidrug-resistance protein, pumps certain cancer drugs out of cancer cells, rendering them ineffective. The researchers looked at a variation in the gene that produces PGP. This mutation reduces PGP function, making it less able to force drugs out of cells.
, 百拇医药
McLeod and colleagues from the University of Aberdeen, the University of Ghana Medical School and the Riyadh Armed Forces Hospital in Saudi Arabia, analyzed the genetic makeup of 1,280 people from 10 ethnic groups.
People who have two versions of the mutated gene--one inherited from each parent--have more than four times less PGP than those with two normal versions of the gene. People may also have one normal gene and one mutated one.
, 百拇医药
Among individuals from Ghana, Kenya, the Sudan, as well as African Americans, frequency of the normal gene ranged from 73% to 84%. In contrast, the frequency was 34% to 59% among British whites, Portuguese, Southwest Asian, Chinese, Filipino and Saudi populations.
Because PGP affects the effectiveness of cancer drugs and also certain HIV medications, the high frequency of the normal gene among individuals of African origin may have relevance to how these individuals are cared for, McLeod told the audience at a press briefing.
, http://www.100md.com
The next step in his research, McLeod said in a statement, will be to see if people with the mutated version of the gene--who likely have less PGP--respond better to chemotherapy than those with a non-mutated, normal version.
``People ask, when will genomic information be of use to individual patients? This presentation shows that today is that day,‘‘ Dr. Jeffrey Trent, of the National Human Genome Research Institute in Bethesda, Maryland, said in summary comments. ``Now we can tailor treatment, dosage, drug combinations.‘‘
, http://www.100md.com
Trent told Reuters Health, ``There‘s no doubt we‘re moving to an area where data rules. The ability to access tools that allow us to link information is going to be the critical common denominator internationally.‘‘
He added, ``The problem is linking the data, merging information between centers while being sensitive to current laws and guidelines that prohibit us from moving data without consent. These are the areas that are going to be particularly challenging to us.‘‘, 百拇医药